Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
dc.contributor.author | Scheid, Christof | |
dc.contributor.author | Pettengell, Ruth | |
dc.contributor.author | Ghielmini, Michele | |
dc.contributor.author | Radford, John A | |
dc.contributor.author | Morgenstern, Godfrey R | |
dc.contributor.author | Stern, Peter L | |
dc.contributor.author | Crowther, Derek | |
dc.date.accessioned | 2010-12-10T14:49:30Z | |
dc.date.available | 2010-12-10T14:49:30Z | |
dc.date.issued | 1995-06 | |
dc.identifier.citation | Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma. 1995, 15 (6):901-6 Bone Marrow Transplant | en |
dc.identifier.issn | 0268-3369 | |
dc.identifier.pmid | 7581089 | |
dc.identifier.uri | http://hdl.handle.net/10541/117679 | |
dc.description.abstract | Chemotherapy induces high remission rates in high-grade lymphoma. However relapse remains a major problem. One approach to this is myeloablative chemotherapy with transplantation of autologous bone marrow or peripheral blood progenitor cells (PBPC). Immunological mechanisms have been suggested to play a role in the prevention of relapse after transplantation. We investigated the recovery of cellular immune functions after high-dose chemotherapy and PBPC transplantation in 5 patients with high grade non-Hodgkin's lymphoma. All patients showed rapid reconstitution of natural killer (NK) and inducible lymphokine-activated killer (LAK)-activity 10-14 days after transplantation. Four of 5 patients showed higher levels of LAK-generation in the post-transplant period compared with levels prior to myeloablative treatment. Absolute lymphocyte counts in peripheral blood reached 1.0 x 10(9)/l between days 10 and 13 with a predominance of CD8+ cells and an inversion of the CD4/CD8 ratio. Four of 5 patients had a transient increase in CD56+ and CD16+ cell counts post-transplant. No change in the proportion of CD25+ cells was noted. These results show that PBPC transplantation leads to a rapid recovery of cellular immune functions after myeloablative chemotherapy and provides evidence for an increased presence of LAK precursor cells early in the post-transplant period which can be activated by IL-2 to exert high levels of cytotoxicity. | |
dc.language.iso | en | en |
dc.subject | Anticancerous Combined Chemotherapy Protocols | en |
dc.subject | Haemapoietic Stem Cell Transplantation | en |
dc.subject | Leukaemia | en |
dc.subject.mesh | Adolescent | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | Bleomycin | |
dc.subject.mesh | Bone Marrow Diseases | |
dc.subject.mesh | Busulfan | |
dc.subject.mesh | Carmustine | |
dc.subject.mesh | Combined Modality Therapy | |
dc.subject.mesh | Cyclophosphamide | |
dc.subject.mesh | Cytarabine | |
dc.subject.mesh | Doxorubicin | |
dc.subject.mesh | Etoposide | |
dc.subject.mesh | Female | |
dc.subject.mesh | Hematopoietic Stem Cell Transplantation | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Killer Cells, Lymphokine-Activated | |
dc.subject.mesh | Killer Cells, Natural | |
dc.subject.mesh | Leukapheresis | |
dc.subject.mesh | Lymphocyte Count | |
dc.subject.mesh | Lymphocyte Subsets | |
dc.subject.mesh | Lymphoma, B-Cell | |
dc.subject.mesh | Lymphoma, Non-Hodgkin | |
dc.subject.mesh | Male | |
dc.subject.mesh | Melphalan | |
dc.subject.mesh | Mesna | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Podophyllotoxin | |
dc.subject.mesh | Precursor Cell Lymphoblastic Leukemia-Lymphoma | |
dc.subject.mesh | Time Factors | |
dc.subject.mesh | Treatment Outcome | |
dc.subject.mesh | Vincristine | |
dc.title | Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma. | en |
dc.type | Article | en |
dc.contributor.department | CRC Department of Immunology, Paterson Institute for Cancer Research, Manchester, UK. | en |
dc.identifier.journal | Bone Marrow Transplantation | en |
html.description.abstract | Chemotherapy induces high remission rates in high-grade lymphoma. However relapse remains a major problem. One approach to this is myeloablative chemotherapy with transplantation of autologous bone marrow or peripheral blood progenitor cells (PBPC). Immunological mechanisms have been suggested to play a role in the prevention of relapse after transplantation. We investigated the recovery of cellular immune functions after high-dose chemotherapy and PBPC transplantation in 5 patients with high grade non-Hodgkin's lymphoma. All patients showed rapid reconstitution of natural killer (NK) and inducible lymphokine-activated killer (LAK)-activity 10-14 days after transplantation. Four of 5 patients showed higher levels of LAK-generation in the post-transplant period compared with levels prior to myeloablative treatment. Absolute lymphocyte counts in peripheral blood reached 1.0 x 10(9)/l between days 10 and 13 with a predominance of CD8+ cells and an inversion of the CD4/CD8 ratio. Four of 5 patients had a transient increase in CD56+ and CD16+ cell counts post-transplant. No change in the proportion of CD25+ cells was noted. These results show that PBPC transplantation leads to a rapid recovery of cellular immune functions after myeloablative chemotherapy and provides evidence for an increased presence of LAK precursor cells early in the post-transplant period which can be activated by IL-2 to exert high levels of cytotoxicity. |